Institutional members access full text with Ovid®

Share this article on:

Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies

Möller, Hans-Jürgena; Llorca, Pierre-Michelb; Sacchetti, Emilioc; Martin, Stephen Dd; Medori, Rossellae; Parellada, EduardfStoRMi Study Group

International Clinical Psychopharmacology: May 2005 - Volume 20 - Issue 3 - p 121-130
Original Articles

The maintained antipsychotic efficacy of risperidone long-acting injectable (RLAI) was investigated in patients with schizophrenia or other psychoses who were transitioned directly from their previous antipsychotic medication. Patients symptomatically stable, but considered to require a treatment change, received 25 mg of RLAI (increased to 37.5 or 50 mg, if necessary) every 2 weeks for 6 months. Assessments included Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression–Severity (CGI-S), Global Assessment of Functioning (GAF), SF-36 Health-Related Quality of Life Questionnaire and Extrapyramidal Symptoms Rating Scale (ESRS). Of 1876 patients enrolled, 74% completed the 6-month study. The most frequent reasons for treatment change were non-compliance (38%), insufficient efficacy (33%) and side-effects (26%). There was a significant reduction from baseline to endpoint in mean total PANSS score and in the scores on all PANSS subscales and symptom factors (P<0.001). CGI-S improved significantly, as did mean GAF score, all factors on the SF-36 and patient satisfaction with treatment. Scores on ESRS showed significant, sustained improvements throughout the study period. Direct initiation of RLAI was effective and well tolerated. RLAI provides an advancement in the treatment options available for a wide range of patients requiring long-term antipsychotic therapy.

aDepartment of Psychiatry, University of Munich, Germany

bService Hospitalier Universitaire, Clermont Ferrand, France

cClinica Psichiatrica, Spedali Civili di Brescia, Brescia, Italy

dUniversity of Sunderland, Fleming Building, Sunderland, Tyne and Wear, UK

eJanssen-Cilag, Medical Affairs EMEA, Belgium

fHospital Clinic de Barcelona, Barcelona, Spain

Correspondence to Professor Hans-Jürgen Möller, Department of Psychiatry, University of Munich, Nussbaumstrasse 7, D-80336 Munich, Germany

Tel: +49 89 5160551; fax: +49 89 51604749;

e-mail: hans-juergen.moeller@med.uni-muenchen.de

Requests for reprints to Dr Rossella Medori, Janssen-Cilag, Medical Affairs EMEA, Belgium.

Tel: +49 2137 955 524; fax: +49 2137 955 485;

e-mail: RMEDORI@jacade.jnj.com

Received 22 October 2004 Accepted 24 February 2005

© 2005 Lippincott Williams & Wilkins, Inc.